tirzepatide cardiovascular outcome trial outcomes of semaglutide and for patients with type 2 diabetes in clinical practice Cardiovascular and Cerebrovascular Outcomes Risk

Last year, Novo Nordisk got approval from Health Canada to market semaglutide under the additional names Plosbrio and Poviztra, which the company said it may use to compete with the cheaper generics

GLP-1 medications, by contrast, have large randomized controlled trials proving 1518% average weight loss over one year

However, if you have IBS and are considering or currently taking a GLP-1 medication, close monitoring and communication with your healthcare team is essential to optimise both conditions effectively

no artificial or synthetic dyes

Keep your injections refrigerated unless we give you different instructions

35 As mentioned, in the absence of T2DM, nearly all glucose filtered through the glomeruli is reabsorbed via SGLTs